FI108229B - Menetelmä farmaseuttisesti käyttökelpoisten pyridopyridatsinoni- ja -pyridatsiinitioniyhdisteiden valmistamiseksi - Google Patents

Menetelmä farmaseuttisesti käyttökelpoisten pyridopyridatsinoni- ja -pyridatsiinitioniyhdisteiden valmistamiseksi Download PDF

Info

Publication number
FI108229B
FI108229B FI941567A FI941567A FI108229B FI 108229 B FI108229 B FI 108229B FI 941567 A FI941567 A FI 941567A FI 941567 A FI941567 A FI 941567A FI 108229 B FI108229 B FI 108229B
Authority
FI
Finland
Prior art keywords
alkyl
formula
hydrogen
nitro
compound
Prior art date
Application number
FI941567A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI941567A (fi
FI941567A0 (fi
Inventor
Robert Alvarez
Robert S Wilhelm
Bradley E Loe
Bruce H Devens
Michael G Martin
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of FI941567A publication Critical patent/FI941567A/fi
Publication of FI941567A0 publication Critical patent/FI941567A0/fi
Application granted granted Critical
Publication of FI108229B publication Critical patent/FI108229B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • C07D213/80Acids; Esters in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30Phthalazines
    • C07D237/32Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
FI941567A 1991-10-09 1994-04-06 Menetelmä farmaseuttisesti käyttökelpoisten pyridopyridatsinoni- ja -pyridatsiinitioniyhdisteiden valmistamiseksi FI108229B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US77567991A 1991-10-09 1991-10-09
US77567991 1991-10-09
US9208398 1992-10-08
PCT/US1992/008398 WO1993007146A1 (en) 1991-10-09 1992-10-08 Benzo and pyrido pyridazinone and pyridazinthione compounds with pde iv inhibiting activity

Publications (3)

Publication Number Publication Date
FI941567A FI941567A (fi) 1994-04-06
FI941567A0 FI941567A0 (fi) 1994-04-06
FI108229B true FI108229B (fi) 2001-12-14

Family

ID=25105161

Family Applications (1)

Application Number Title Priority Date Filing Date
FI941567A FI108229B (fi) 1991-10-09 1994-04-06 Menetelmä farmaseuttisesti käyttökelpoisten pyridopyridatsinoni- ja -pyridatsiinitioniyhdisteiden valmistamiseksi

Country Status (20)

Country Link
EP (1) EP0612321B1 (ko)
JP (1) JP3245165B2 (ko)
KR (1) KR100263494B1 (ko)
AT (1) ATE183745T1 (ko)
AU (1) AU670544B2 (ko)
CA (1) CA2117059C (ko)
DE (1) DE69229874T2 (ko)
DK (1) DK0612321T3 (ko)
ES (2) ES2135416T3 (ko)
FI (1) FI108229B (ko)
GR (1) GR3030969T3 (ko)
HU (2) HUT66969A (ko)
IL (1) IL103388A (ko)
MX (1) MX9205794A (ko)
NO (1) NO302888B1 (ko)
NZ (1) NZ244660A (ko)
PT (1) PT100938B (ko)
TW (1) TW365606B (ko)
WO (1) WO1993007146A1 (ko)
ZA (1) ZA927755B (ko)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200689D0 (en) * 1992-01-14 1992-03-11 Rhone Poulenc Agriculture New compositions of matter
GB9314412D0 (en) * 1993-07-13 1993-08-25 Rhone Poulenc Agriculture New compositions of matter
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
US5466697A (en) * 1994-07-13 1995-11-14 Syntex (U.S.A.) Inc. 8-phenyl-1,6-naphthyridin-5-ones
US5817670A (en) * 1994-08-29 1998-10-06 Yamanouchi Pharmaceutical Co., Ltd. Naphthyridine derivatives and pharmaceutical compositions thereof
GB9712761D0 (en) * 1997-06-17 1997-08-20 Chiroscience Ltd Quinolines and their therapeutic use
US6069151A (en) * 1996-11-06 2000-05-30 Darwin Discovery, Ltd. Quinolines and their therapeutic use
ES2137113B1 (es) * 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
AU753576B2 (en) * 1997-12-15 2002-10-24 Altana Pharma Ag Dihydrobenzofurans
EP0934933A1 (en) * 1998-02-06 1999-08-11 Byk Gulden Lomberg Chemische Fabrik GmbH Phthalazinones
IT1303272B1 (it) * 1998-10-29 2000-11-06 Zambon Spa Derivati triciclici inibitori della fosfodiesterasi 4
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
AU777012B2 (en) 1999-08-21 2004-09-30 Takeda Gmbh Synergistic combination of PDE inhibitors and beta 2 adrenoceptor agonist
NZ527424A (en) * 2001-02-15 2005-02-25 Altana Pharma Ag Phthalayinone-piperidino-derivatives as PDE4 inhibitors
NZ529363A (en) 2001-04-25 2005-08-26 Altana Pharma Ag Novel Piperazino-derivatives
CN1503792A (zh) 2001-04-25 2004-06-09 ��̹��ҽҩ��˾ 新的酞嗪酮
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
EP1542987A1 (en) * 2002-08-10 2005-06-22 ALTANA Pharma AG Piperidine-n-oxide-derivatives
AU2003260376A1 (en) 2002-08-10 2004-03-11 Altana Pharma Ag Piperidine-pyridazones and phthalazones as pde4 inhibitors
ES2211344B1 (es) * 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2004226353A1 (en) 2003-04-01 2004-10-14 Laboratoires Serono Sa Inhibitors of phosphodiesterases in infertility
WO2005075456A1 (en) 2004-02-04 2005-08-18 Altana Pharma Ag 2-(piperidin-4-yl) -4, 5-dihydro-2h-pyridazin-3-one derivatives as pde4 inhibitors
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
PL383550A1 (pl) * 2007-10-15 2009-04-27 Uniwersytet Łódzki Nowe pochodne benzeno- i pirydopirydazynonów
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA3100941C (en) 2011-03-01 2024-03-05 Synergy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
JP6499591B2 (ja) 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
CA2906008C (en) 2013-03-13 2019-07-09 Flatley Discovery Lab, Llc Pyridazinone compounds and methods for the treatment of cystic fibrosis
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
KR102456567B1 (ko) 2013-08-09 2022-10-19 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
EP3265453B1 (en) * 2015-03-05 2022-06-29 Boehringer Ingelheim International GmbH New pyridinones and isoquinolinones as inhibitors of the bromodomain brd9
JP6837052B2 (ja) * 2016-03-09 2021-03-03 日本曹達株式会社 ピリジン化合物およびその用途
LT3442972T (lt) 2016-04-15 2020-06-10 Abbvie Inc. Bromodomeno inhibitoriai
EP3972599A1 (en) 2019-05-21 2022-03-30 Ardelyx, Inc. Combination for lowering serum phosphate in a patient
FR3105254B1 (fr) 2019-12-19 2022-08-12 Syctom Lagence Metropolitaine Des Dechets Menagers Installation et procédé de gazéification hydrothermale de biomasse

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2805344B2 (ja) * 1989-07-11 1998-09-30 昭和電工株式会社 オレフィン重合触媒の製造方法およびオレフィンの重合方法
WO1991012251A1 (en) * 1990-02-19 1991-08-22 Chugai Seiyaku Kabushiki Kaisha Novel fused heterocyclic compound and antiasthmatic agent prepared therefrom

Also Published As

Publication number Publication date
AU670544B2 (en) 1996-07-25
JP3245165B2 (ja) 2002-01-07
FI941567A (fi) 1994-04-06
ATE183745T1 (de) 1999-09-15
HUT66969A (en) 1995-01-30
ES2135416T3 (es) 1999-11-01
CA2117059A1 (en) 1993-04-15
PT100938A (pt) 1993-10-29
CA2117059C (en) 2003-05-20
ES2105920B1 (es) 1998-07-01
PT100938B (pt) 1999-10-29
IL103388A (en) 1997-09-30
EP0612321A1 (en) 1994-08-31
NO941210L (no) 1994-04-05
DK0612321T3 (da) 1999-12-13
ES2105920A1 (es) 1997-10-16
HU9400949D0 (en) 1994-06-28
NO302888B1 (no) 1998-05-04
WO1993007146A1 (en) 1993-04-15
ZA927755B (en) 1994-04-08
KR100263494B1 (ko) 2000-08-01
HU210814A9 (en) 1995-08-28
IL103388A0 (en) 1993-03-15
GR3030969T3 (en) 1999-11-30
JPH07500321A (ja) 1995-01-12
EP0612321B1 (en) 1999-08-25
AU2781592A (en) 1993-05-03
FI941567A0 (fi) 1994-04-06
MX9205794A (es) 1993-04-01
DE69229874T2 (de) 1999-12-09
NO941210D0 (no) 1994-04-05
NZ244660A (en) 1995-05-26
DE69229874D1 (de) 1999-09-30
KR940702868A (ko) 1994-09-17
TW365606B (en) 1999-08-01

Similar Documents

Publication Publication Date Title
FI108229B (fi) Menetelmä farmaseuttisesti käyttökelpoisten pyridopyridatsinoni- ja -pyridatsiinitioniyhdisteiden valmistamiseksi
FI106960B (fi) Menetelmä terapeuttisesti aktiivisten 1-fenyyli-pyrido[2,3-d]pyrimidiini-2,4-dioni- ja 2-onijohdannaisten valmistamiseksi
AU754734B2 (en) Indazole bioisostere replacement of catechol in therapeutically active compounds
JP3270830B2 (ja) 化合物
DE60221098T2 (de) Kondensierte heterocyclische derivate
AU2007292155B2 (en) Imidazole derivative
JP7191826B2 (ja) 三環式rhoキナーゼ阻害剤
ES2548882T3 (es) Moduladores del receptor de prostaciclina (PGl2) útiles para el tratamiento de trastornos relacionados con los mismos
JP2015134805A (ja) Nadphオキシダーゼインヒビターとしてのピラゾロピリジン誘導体を含有する医薬組成物
JP2008503531A (ja) ピリダジン−3(2h)−オン誘導体およびpde4の阻害剤としてのそれらの使用
JP2005506350A (ja) サイトカイン阻害薬としての1,4−二置換ベンゾ−縮合尿素化合物
EA011634B1 (ru) 3-[4-гетероциклил-1,2,3-триазол-1-ил]-n-арилбензамиды в качестве ингибиторов продуцирования цитокинов, предназначенные для лечения хронических воспалительных заболеваний
NO873432L (no) Fremgangsmaate for fremstilling av imidazolforbindelser.
EA027244B1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
MXPA05007407A (es) Derivados de urea ciclica, su preparacion y su utilizacion farmaceutica como inhibidores de quinasas.
KR20130089245A (ko) 1-페닐-치환된 헤테로시클릴 유도체 및 프로스타글란딘 d2 수용체 조절자로서 이의 용도
US20080176894A1 (en) Novel aminopyridine-derivatives
CA3128846A1 (en) Difluoromethylene compound
BRPI0921369B1 (pt) Composto modulador do receptor de prostaciclina (pgi2), sua composição, sua composição farmacêutica, seus usos, bem como processos para a preparação das referidas composições
JP2898256B2 (ja) 特定の4−アリール−5−カルバモイル−1,4−ジヒドロピリジンを含む医薬組成物
JPWO2003004497A1 (ja) 新規複素環化合物
JP2006519798A (ja) 5HT2c受容体に活性を有する化合物及びその使用
RU2676332C1 (ru) Способ получения 3-замещённых сложных эфиров (индол-1-ил)-уксусной кислоты
KR20070107082A (ko) 2-설피닐- 및 2-설포닐-치환 이미다졸 유도체 및 시토킨억제제로서의 그들의 용도
EP2888261B1 (en) Antagonists of chemokine receptors